CBD Regulation in France: What Professionals Should Check Before Selling

Why compliance needs to be checked product by product

Selling CBD in France requires more than checking a THC result. Professional buyers need to establish the product’s composition, intended use and legal category before ordering, then keep records that connect those checks to the stock they sell.

The regulatory framework can change quickly, particularly for cannabinoid derivatives and ingestible formats. For a professional list, compliance should be part of purchasing, onboarding and restocking, not a one-off check when a new supplier is first contacted.

The THC threshold applicable in France

In France, CBD flowers, resin and derived products must not exceed 0.3% Delta-9-THC.

The French Conseil d’État ruling of 29 December 2022 removed the ban on the retail sale of raw CBD flowers and leaves that remain below the applicable THC threshold. Compliant flowers and resin can be sold, but the threshold must be supported by reliable product documentation rather than assumed from a supplier’s product name or catalogue description.

What a useful laboratory report should show

A certificate of analysis is one of the core records to request for flowers, CBD hash or other products where cannabinoid content is relevant. It should be traceable to the item being supplied, ideally through a batch or lot reference. A report that cannot be connected to the stock received offers limited practical protection during a review.

Before listing a product, professional buyers should check whether the available report clearly identifies:

• the product or batch reference;
• the laboratory or testing provider;
• the cannabinoid results, including Delta-9-THC;
• the date of analysis;
• a result consistent with the product being sold.

A lab report does not remove every compliance obligation, but it is an essential part of traceability. Refresh it when a reseller receives a new batch rather than reusing it indefinitely for stock with a different lot number.

Product categories do not face the same rules

A common error is to apply the same compliance logic to every CBD format. In France, the legal position depends heavily on the product category and how it is presented to the market.

For ingestible CBD, check the specific ingredient’s Novel Food authorisation and the intended conditions of use before purchasing. A supplier listing or batch analysis is not evidence of permission to market a food. French enforcement of unauthorised CBD foods was reiterated by the agriculture ministry in May 2026.

By contrast, raw CBD flowers and resin intended for non-ingestible use, e-liquids and cosmetics remain legal in France when they meet the applicable requirements, including the 0.3% Delta-9-THC threshold. This distinction matters for both stock selection and product copy. A product format, label or sales description should not imply an ingestible use where that would conflict with the current French position.

Novel Food status and the limits of safety references

Verify any claimed food authorisation against the European Commission’s Union list and its conditions of use. An application, safety assessment or history of sale is not equivalent to an authorisation covering the proposed product.

EFSA’s February 2026 assessment addressed specific highly purified CBD formulations and retained important safety uncertainties. A provisional scientific assessment is not permission to sell an ingestible product.

For a French CBD reseller, this provisional scientific assessment should not be used as a marketing claim, a recommended serving size or evidence that ingestible CBD products may be sold. The relevant commercial point remains the absence of Novel Food authorisation and the French enforcement position applicable since May 2026.

Labelling should match the product and its permitted use

Labelling is not a design exercise. It must allow the product to be identified, traced and presented without misleading claims. The exact requirements can differ by format, so a flower jar, an e-liquid bottle and a cosmetic product should not be reviewed against a single generic checklist.

For professional buyers, practical checks include the product identity, batch reference, responsible economic operator details where applicable, ingredient information for relevant formats, warnings and any required language elements. The label should also remain consistent with the evidence held in the product file.

Health, therapeutic or medicinal claims create particular risk. Statements suggesting that CBD treats pain, anxiety, insomnia or another medical condition should not appear on labels, product pages, point-of-sale materials or reseller communications. Commercial descriptions should remain factual, focusing on the format, traceability, declared composition where documented and relevant product characteristics.

Keeping online listings aligned with physical stock

E-commerce businesses should compare their product pages with the label and technical file before publishing. This is especially important when product data is imported from a wholesale feed, translated for a French storefront or reused across several channels.

A useful internal review can cover the product title, category, cannabinoid wording, batch documentation, claims, warnings and product images. If a supplier changes a formula, a label or a batch, the online listing may also need updating. This process helps prevent a compliant physical product from being paired with inaccurate or outdated digital content.

High-risk cannabinoid derivatives require constant vigilance

France has taken a restrictive approach to several semi-synthetic and hydrogenated cannabinoids. H4CBD, H2CBD, THCP, HHC, HHC-O, HHCP and related derivatives have been classified as narcotics by the ANSM since 2023 and 2024.

Their production, sale, possession and use are illegal in France. This area has changed several times in recent years, so it should not be treated as a stable product opportunity simply because a compound is offered in another market or appears in an overseas supplier catalogue.

Before considering any unfamiliar cannabinoid, a business should verify its current French status through authoritative sources and obtain specialist advice where needed. A compliant CBD supplier should be able to provide clear ingredient information, not vague terms that make the active compounds difficult to identify.

VAT and commercial records for smoking and vaping products

France’s current tax position applies the standard 20% VAT rate to CBD products intended for smoking, including flowers, resin or hash, and pre-rolls. A reduced VAT rate should not be assumed for these categories.

This point affects margin calculations, invoicing and retail pricing. Wholesale buyers should ensure that their accounting treatment, supplier invoices and product classifications are coherent, particularly when a professional catalogue combines different product families.

Beyond VAT, businesses benefit from maintaining a structured compliance file for each reference. It can include purchase invoices, batch records, laboratory reports, labels, product specifications and supplier correspondence. This record-keeping is useful for internal quality control and makes it easier to investigate a question raised by a marketplace, retailer, authority or customer.

Building a more reliable purchasing process

For retailers and distributors, the strongest approach is to make compliance checks repeatable. Instead of relying on informal assurances, establish a clear approval process before a reference enters the catalogue and repeat key checks at each restocking stage.

A professional supplier such as Abican can be assessed not only on MOQ, tiered pricing or delivery terms, but also on the clarity of its product documentation and traceability process. Buyers should ask direct questions when documents are incomplete, a batch reference is missing or a product presentation does not match its category.

This information is provided for general informational purposes only and does not constitute legal, tax or regulatory advice. Professional buyers should verify current requirements with a qualified advisor or the relevant competent authority before making commercial decisions.